Business CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
Business NACCO outlines significant capital investments for 2026 amid utility coal mining recovery and new infrastructure contracts
Business Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs